menu
    • menu
    [{"orgOrder":0,"company":"Zelira Therapeutics","sponsor":"Zelira Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Cannabinoid-based Product","moa":"CB receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Zelira Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Zelira Therapeutics \/ Zelira Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Zelira Therapeutics \/ Zelira Therapeutics"},{"orgOrder":0,"company":"Zelira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ZLT-101","moa":"","graph1":"Sleep","graph2":"Phase I\/ Phase II","graph3":"Zelira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"","sponsorNew":"Zelira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Zelira Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Zelira Therapeutics","sponsor":"Forman Investment Trust","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Zelira Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Zelira Therapeutics \/ Forman Investment Trust","highestDevelopmentStatusID":"1","companyTruncated":"Zelira Therapeutics \/ Forman Investment Trust"},{"orgOrder":0,"company":"Zelira Therapeutics","sponsor":"Forman Investment Trust","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Zelira Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Zelira Therapeutics \/ Forman Investment Trust","highestDevelopmentStatusID":"1","companyTruncated":"Zelira Therapeutics \/ Forman Investment Trust"},{"orgOrder":0,"company":"Zelira Therapeutics","sponsor":"Forman Investment Trust","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Zelira Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Zelira Therapeutics \/ Forman Investment Trust","highestDevelopmentStatusID":"14","companyTruncated":"Zelira Therapeutics \/ Forman Investment Trust"}]

    Find Clinical Drug Pipeline Developments & Deals by Zelira Therapeutics

    Menu

    Zelira Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Zelira Therapeutics

                            Australia arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Zelira Therapeutics

                            Australia arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrahydrocannabinol,Cannabidiol

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Forman Investment Trust

                            Deal Size : $3.2 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Zelira’s HOPE® SPV Receives US$681,000 Third Tranche of Funding

                            Details : The net proceeds will be used to support the HOPE® 1 formal FDA clinical program. Zelira has established a SPV to conduct FDA clinical trials for Zelira’s proprietary and patent protected HOPE 1.

                            Brand Name : Hope 1

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 23, 2024

                            Lead Product(s) : Tetrahydrocannabinol,Cannabidiol

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Forman Investment Trust

                            Deal Size : $3.2 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Zelira Therapeutics

                            Australia arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Zelira Therapeutics

                            Australia arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrahydrocannabinol,Cannabidiol

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Forman Investment Trust

                            Deal Size : $3.2 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Zelira's HOPE® SPV receives US$819,000 second tranche of funding

                            Details : The net proceeds will be used to support the HOPE® 1 formal FDA clinical program. Zelira has established a SPV to conduct FDA clinical trials for Zelira’s proprietary and patent protected HOPE 1.

                            Brand Name : Hope 1

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 08, 2024

                            Lead Product(s) : Tetrahydrocannabinol,Cannabidiol

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Forman Investment Trust

                            Deal Size : $3.2 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Zelira Therapeutics

                            Australia arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Zelira Therapeutics

                            Australia arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrahydrocannabinol,Cannabidiol

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Forman Investment Trust

                            Deal Size : $3.2 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Zelira Initiates HOPE® Trial After Closing First Round of HOPE SPV Fundraise

                            Details : The net proceeds will be used to support the HOPE® 1 formal FDA clinical program. Zelira has established a SPV to conduct FDA clinical trials for Zelira’s proprietary and patent protected HOPE 1.

                            Brand Name : Hope 1

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 17, 2023

                            Lead Product(s) : Tetrahydrocannabinol,Cannabidiol

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Forman Investment Trust

                            Deal Size : $3.2 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Zelira Therapeutics

                            Australia arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Zelira Therapeutics

                            Australia arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZLT-101

                            Therapeutic Area : Sleep

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zelira Therapeutics Meets Primary Endpoints for Phase (1b/2a) Medicinal Cannabis Trial for Insomnia

                            Details : 23 chronic insomnia patients treated with ZLT-101, Zelira's proprietary and patented medicinal cannabis formulation, demonstrated statistically significant improvement in Insomnia Severity Index.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 18, 2020

                            Lead Product(s) : ZLT-101

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Zelira Therapeutics

                            Australia arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Zelira Therapeutics

                            Australia arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabinoid-based Product

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Recipient : Parkinson’s Foundation

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Zelira Therapeutics collaborates with Parkinson's Foundation

                            Details : Zelira Therapeutics is assisting Parkinson’s Foundation in the development of a survey to understand the current use and perceived benefits of medical cannabis among people with PD.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 28, 2020

                            Lead Product(s) : Cannabinoid-based Product

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Recipient : Parkinson’s Foundation

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth